Improving The Efficacy And Availability Of Stem Cell Transplant Therapies For Hematopoietic Stem Cell Transplantation

Abstract

Recent developments in pre-transplant preparative regimens as well as post-transplant care have made incremental but definite improvements in post-transplant survival. Graft engineering has also helped to facilitate the removal of cells which cause graft-versus-host disease (GVHD), the eradication of cells which might cause relapse, the expansion of donor cells when there is an inadequate cell dose, and the addition of selected cells to improve graft function with augmented anti-tumor or anti-infective properties. These advances help enhance the safety, efficacy and availability of HSCT, ensuring that this modality of treatment remains an important part of the continuum of care of patients of potentially fatal cancers and blood diseases.

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

“…Of note, the cases reported in this observational study [42] ranged from March 2008 through December 2009. Lack of improvement in patient outcomes might be partially explained by the overall improvement in stem cell transplantation in the past decade [51].…”